Literature DB >> 25687833

Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities.

Christopher B Benton1, Maria Tanaka2, Catherine Wilson2, Sherry Pierce3, Lingsha Zhou3, Jorge Cortes3, Hagop Kantarjian3, Srdan Verstovsek4.   

Abstract

Chromosome 12 (Chr12) abnormalities have been described for individual patients with Philadelphia chromosome-negative myeloproliferative neoplasms (Ph-neg MPN), however the frequency, characteristics, and outcomes of such patients as a whole have not been investigated. We reviewed a database of 1787 consecutive Ph-neg MPN patients seen at our institution and determined that 2% of Ph-neg MPN patients harbored an alteration involving Chr12 by cytogenetic evaluation. Retrospective chart review revealed that patients with Chr12 abnormalities had a higher likelihood of having myelofibrosis (MF) compared to patients without a Chr12 abnormality, and were more likely to have post-polycythemia vera MF. The most common alterations in Chr12 in MF patients involved 12q13, 12q15, 12q24, and trisomy 12, and >40% of Chr12 Ph-neg MPN patients had cytogenetic evolution. Chr12 abnormalities did not significantly correlate with JAK2 status, progression to acute myeloid leukemia, or survival, however patients with 12q24 abnormalities trended toward poorer outcomes.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chromosome aberrations; Myelofibrosis; Myeloproliferative neoplasms; Polycythemia vera

Mesh:

Year:  2015        PMID: 25687833      PMCID: PMC4847531          DOI: 10.1016/j.leukres.2015.01.012

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  19 in total

1.  Lnk constrains myeloproliferative diseases in mice.

Authors:  Alexey Bersenev; Chao Wu; Joanna Balcerek; Jiang Jing; Mondira Kundu; Gerd A Blobel; Kudakwashe R Chikwava; Wei Tong
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

2.  Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders.

Authors:  R McClure; M Mai; T Lasho
Journal:  Leukemia       Date:  2006-01       Impact factor: 11.528

3.  Recurrent chromosomal aberration at 12q15 in chronic idiopathic myelofibrosis with or without JAK2(V617F) mutation.

Authors:  K Ohyashiki; T Tauchi; M Kuroda; A Kodama; J H Ohyashiki
Journal:  Leukemia       Date:  2007-04-19       Impact factor: 11.528

Review 4.  The adaptor Lnk (SH2B3): an emerging regulator in vascular cells and a link between immune and inflammatory signaling.

Authors:  Julie Devallière; Béatrice Charreau
Journal:  Biochem Pharmacol       Date:  2011-06-24       Impact factor: 5.858

5.  Frequency of structural abnormalities of the long arm of chromosome 12 in myelofibrosis with myeloid metaplasia.

Authors:  Joris Andrieux; Jean Loup Demory; Pierre Morel; Isabelle Plantier; Brigitte Dupriez; Marie Thérèse Caulier; Francis Bauters; Jean Luc Laï
Journal:  Cancer Genet Cytogenet       Date:  2002-08

6.  3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice.

Authors:  Kazuhiko Ikeda; Philip J Mason; Monica Bessler
Journal:  Blood       Date:  2011-04-01       Impact factor: 22.113

7.  Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

Authors:  Stephen T Oh; Erin F Simonds; Carol Jones; Matthew B Hale; Yury Goltsev; Kenneth D Gibbs; Jason D Merker; James L Zehnder; Garry P Nolan; Jason Gotlib
Journal:  Blood       Date:  2010-04-19       Impact factor: 22.113

8.  Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes.

Authors:  Anne Etienne; Nadine Carbuccia; José Adélaïde; Ismahane Bekhouche; Virginie Rémy; Claudine Sohn; Danielle Sainty; Jean-Albert Gastaut; Sylviane Olschwang; Daniel Birnbaum; Marie-Joëlle Mozziconacci; Max Chaffanet
Journal:  Cancer Genet Cytogenet       Date:  2007-07-01

9.  Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99.

Authors:  P Johansson; J Kutti; B Andréasson; S Safai-Kutti; L Vilén; H Wedel; B Ridell
Journal:  J Intern Med       Date:  2004-08       Impact factor: 8.989

10.  Identification of a HMGA2-EFCAB6 gene rearrangement following next-generation sequencing in a patient with a t(12;22)(q14.3;q13.2) and JAK2V617F-positive myeloproliferative neoplasm.

Authors:  S Eric Martin; Mark Sausen; Abraham Joseph; Brewster F Kingham; Eric S Martin
Journal:  Cancer Genet       Date:  2012-06
View more
  6 in total

1.  Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53.

Authors:  Bridget K Marcellino; Ronald Hoffman; Joseph Tripodi; Min Lu; Heidi Kosiorek; John Mascarenhas; Raajit K Rampal; Amylou Dueck; Vesna Najfeld
Journal:  Blood Adv       Date:  2018-12-26

2.  Chromosome 12 Rearrangement in an Adolescent with Primary Myelofibrosis.

Authors:  Moeinadin Safavi; Atoosa Gharib; Mohammad Taghi Haghi Ashtiani; Poorya Salajegheh; Mohammad Vasei
Journal:  Indian J Hematol Blood Transfus       Date:  2018-12-06       Impact factor: 0.900

Review 3.  From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.

Authors:  Alessandro M Vannucchi
Journal:  Haematologica       Date:  2016-11-24       Impact factor: 9.941

4.  Hmga2 promotes the development of myelofibrosis in Jak2V617F knockin mice by enhancing TGF-β1 and Cxcl12 pathways.

Authors:  Avik Dutta; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2017-06-21       Impact factor: 22.113

Review 5.  Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.

Authors:  Ruth Stuckey; María Teresa Gómez-Casares
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

6.  The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.

Authors:  Kazuhiko Ikeda; Koki Ueda; Takahiro Sano; Kazuei Ogawa; Takayuki Ikezoe; Yuko Hashimoto; Soji Morishita; Norio Komatsu; Hitoshi Ohto; Yasuchika Takeishi
Journal:  Intern Med       Date:  2017-07-01       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.